Imperial College London
Alternate

ProfessorRosemaryBoyton

Faculty of Medicine, Department of Infectious Disease

Professor of Immunology and Respiratory Medicine
 
 
 
//

Contact

 

r.boyton

 
 
//

Location

 

8N22Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Lin:2021:rs.3.rs-755879/v1,
author = {Lin, S and Kennedy, NA and Saifuddin, A and Sandoval, DM and Reynolds, C and Seoane, RC and Kottoor, S and Pieper, F and Lin, K-M and Butler, DK and Chanchlani, N and Nice, R and Chee, D and Bewshea, C and Janjua, M and McDonald, TJ and Sebastian, S and Alexander, JL and Constable, L and Lee, JC and Murray, CD and Hart, AL and Irving, PM and Jones, G-R and Kok, KB and Lamb, CA and Lees, CW and Altmann, DM and Boyton, RJ and Goodhand, JR and Powell, N and Ahmad, T},
doi = {rs.3.rs-755879/v1},
title = {Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients},
url = {http://dx.doi.org/10.21203/rs.3.rs-755879/v1},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:title>Abstract</jats:title>        <jats:p>To inform healthcare policy for immunosuppressed patients there is a need to define SARS-CoV-2 vaccine responses. Here we report SARS-CoV-2 vaccine-induced antibody and T cell responses in patients treated with anti-tumour necrosis factor (anti-TNF), a commonly used biologic in inflammatory diseases, compared to patients treated with vedolizumab, a gut-specific antibody targeting integrin a4b7 that does not impair systemic immunity. In anti-TNF recipients, the magnitude of anti-SARS-CoV2 antibodies was reduced five-fold, and rapidly decayed towards the seroconversion threshold by 14 weeks after second dose of vaccine. In contrast, anti-SARS-CoV-2 antibodies were sustained up to 16 weeks in vedolizumab-treated patients. Anti-SARS-CoV2 antibody decay was not observed in vaccinated patients previously infected with SARS-CoV-2. T cell responses were absent in one-fifth of anti-TNF and vedolizumab-treated patients after a second dose of either vaccine. Our data have important implications for anti-TNF recipients, including the need for vaccine prioritization, booster doses, and social distancing strategies.</jats:p>
AU  - Lin,S
AU  - Kennedy,NA
AU  - Saifuddin,A
AU  - Sandoval,DM
AU  - Reynolds,C
AU  - Seoane,RC
AU  - Kottoor,S
AU  - Pieper,F
AU  - Lin,K-M
AU  - Butler,DK
AU  - Chanchlani,N
AU  - Nice,R
AU  - Chee,D
AU  - Bewshea,C
AU  - Janjua,M
AU  - McDonald,TJ
AU  - Sebastian,S
AU  - Alexander,JL
AU  - Constable,L
AU  - Lee,JC
AU  - Murray,CD
AU  - Hart,AL
AU  - Irving,PM
AU  - Jones,G-R
AU  - Kok,KB
AU  - Lamb,CA
AU  - Lees,CW
AU  - Altmann,DM
AU  - Boyton,RJ
AU  - Goodhand,JR
AU  - Powell,N
AU  - Ahmad,T
DO  - rs.3.rs-755879/v1
PY  - 2021///
TI  - Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients
UR  - http://dx.doi.org/10.21203/rs.3.rs-755879/v1
ER  -
Download